Evidence-based recommendations for the management of ankylosing spondylitis: Systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists

Rheumatology

Volumn 47, Issue 3, 2008, Pages 355-361

  Sidiropoulos, P I ^a   Hatemi, G ^b   Song, I H ^c   Avouac, J ^d   Collantes, E ^e   Hamuryudan, V ^b   Herold, M ^f   Kvien, T K ^g   Mielants, H ^h   Mendoza, J M ⁱ   Olivieri, I ^j   Ostergaard M ^k   Schachna, L ^l   Sieper, J ^c   Boumpas, D T ^a   Dougados, M ^d  

^a UNIVERSITY OF CRETE   (Greece)

^b ISTANBUL UNIVERSITY   (Turkey)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Paris Descartes University ^*  (France)

^e HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^f INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^g DIAKONHJEMMET HOSPITAL   (Norway)

^h GHENT UNIVERSITY HOSPITAL   (Belgium)

ⁱ HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^j SAN CARLO HOSPITAL   (Italy)

^k Mental Health Services CPH   (Denmark)

^l AUSTIN HEALTH   (Australia)

more..

Author keywords

Ankylosing spondylitis; COX II inhibitors; Diagnosis; Monitoring; Non steroidal anti inflammatory drugs; Recommendations; Systemic literature search; Treatment

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETORICOXIB; GASTROINTESTINAL MUCOSA PROTECTIVE AGENT; HLA B27 ANTIGEN; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PLACEBO; SALAZOSULFAPYRIDINE;

ANKYLOSING SPONDYLITIS; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC PAIN; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS DEVELOPMENT; DAILY LIFE ACTIVITY; DELPHI STUDY; DIAGNOSTIC ACCURACY; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; ENTERITIS; ENTHESITIS; EVIDENCE BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; IRIDOCYCLITIS; LOW BACK PAIN; MEDLINE; MORNING STIFFNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; OSTEOPOROSIS; PATIENT REFERRAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS; SACROILIITIS; SPINE RADIOGRAPHY; SPONDYLITIS; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL COOPERATION; MALE; MONITORING, PHYSIOLOGIC; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPONDYLITIS, ANKYLOSING;

EID: 39449097587     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem348     Document Type: Article

References (93)

1. van der Linden SM, Valkenburg HA, de Jongh BM, Cats A. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum 1984;27:241-9.
2. Gran JT, Husby G, Hordvik M. Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway. Ann Rheum Dis 1985;44:359-67.
3. Braun J, Bollow M, Remlinger G et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998;41:58-67.
4. Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis - results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 2000;27:613-22.
5. Feldtkeller E, Khan MA, van der Heijde D, van der LS, Braun J. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 2003;23:61-6.
6. Braun J, Landewe R, Hermann KG et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006;54:1646-52.
7. Davis JC Jr, van der Heijde D, Braun J et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
8. van der Heijde D, Kivitz A, Schiff MH et al. Efficacy and safety of adalimumab in patients Mth ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46.
9. Zochling J, van der Heijde D, Burgos-Vargas R et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-52.
10. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. Br Med J 1999;318:593-6.
11. Calin A, Kaye B, Stemberg M, Antell B, Chan M. The prevalence and nature of back pain in an industrial complex: A questionnaire and radiographic and HLA analysis. Spine 1980;5:201-5.
12. Mau W, Zeidler H, Mau R et al. Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup. J Rheumatol 1988;15:1109-14.
13. Brandt HC, Spiller I, Song IH, Vahldiek JL, Rudwaleit M, Sieper J. Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis. Ann Rheum Dis 2007:66(11):1479-84.
14. Sieper J, Rudwaleit M. Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care. Ann Rheum Dis 2005;64:659-63.
15. Vinje O, Dale K, Moller P. Radiographic changes, HLA B27 and back pain in patients with psoriasis or acute anterior uveitis. Scand J Rheumatol 1983;12:219-24.
16. Calin A, Fries JF. Striking prevalence of ankylosing spondylitis in "healthy" w27 positive males and females. N Engl J Med 1975;293:835-9.
17. Sany J, Rosenberg F, Panis G, Serre H. Unclassified HLA-B27 inflammatory rheumatic diseases: Followup of 23 patients. Arthritis Rheum 1980;23:258-9.
18. Schattenkirchner M, Kruger K. Natural course and prognosis of HLA-B27-positive oligoarthritis. Clin Rheumatol 1987;6(Suppl 2):83-6.
19. Bingham WF. The role of HLA B27 in the diagnosis and management of low-back pain and sciatica. J Neurosurg 1977;47:561-6.
20. Linder R, Hoffmann A, Brunner R. Prevalence of the spondyloarthritides in patients with uveitis. J Rheumatol 2004;31:2226-9.
21. Rosenbaum JT. Characterization of uveitis associated with spondyloarthritis. J Rheumatol 1989;16:792-6.
22. Chung YM, Yeh TS, Liu JH. Clinical manifestations of HLA-B27-positive acute anterior uveitis in Chinese. Zhonghua Yi Xue Za Zhi 1989;43:97-104.
23. Lenoch F, Kralik V, Bartos J. Rheumatic iritis and iridocyclitis. Ann Rheum Dis 1959;18:45-8.
24. Santin M, Mascaro J, Nolla JM, Roca G, Badrinas F. Uveitis associated with spondyloarthritis. J Rheumatol 1990; 17:854.
25. Blackburn WD Jr, Alarcon GS, Ball GV. Evaluation of patients with back pain of suspected inflammatory nature. Am J Med 1988;85:766-70.
26. Brandt J, Bollow M, Haberle J et al. Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: Many, but not all patients with sacroiliitis have spondyloarthropathy. Rheumatology 1999;38:831-6.
27. Underwood MR, Dawes P. Inflammatory back pain in primary care. Br J Rheumatol 1995;34:1074-7.
28. van der Haijde D, Bellamy N, Calin A, Dougados M, Khan MA, van der Linden S. Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol 1997;24:2225-9.
29. Rudwaleit M, Baraliakos X, Listing J, Sieper J, Braun J. The course of radiographic spinal lesions in patients with early ankylosing spondylitis over a 2-year follow-up period. Ann Rheum Dis 2005;64(Suppl III):335.
30. Amor B, Santos RS, Nahal R, Listrat V, Dougados M. Predictive factors for the longterm outcome of spondyloarthropathies. J Rheumatol 1994;21:1883-7.
31. van Tubergen A, Landewe R, Heuft-Dorenbosch L et al. Assessment of disability with the World Health Organisation Disability Assessment Schedule II in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:140-5.
32. Falkenbach A, Franke A, van der Linden S. Facfors associated with body function and disability in patients with ankylosing spondylitis: A cross-sectional study. J Rheumatol 2003;30 2186-92.
33. Boonen A, Chorus A. Miedema H et al. Withdrawal from labour force due to work disability in patients with ankylosing spondylitis. Ann Rheum Dis 2001;60:1033-9.
34. Maksymowych WP, Jhangri GS, Fitzgerald AA et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60mg versus 10 mg) in the treatment of nonsteroidal antinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002;46:766-73.
35. Maksymowych WP, Jhangri GS, LeClerce S, Skeith K, Yan A, Russell AS. An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol 1998;25:714-7.
36. Maksymowych WP, Lambert R, Jhangri GS et al. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate. therapy. J Rheumatol 2001;28:144-55.
37. Haibel H, Brandt J, Rudwaleit M, Soerensen H, Sieper J, Braun J. Treatment of active ankylosing spondylitis with pamidronate. Rheumatology 2003;42:1018-20.
38. Grover R, Shanker S, Aneja R, Marwaha V, Gupta R, Kumar A. Treatment of ankylosing spondylitis with pamidronate: An open label study. Ann Rheum Dis 2006;65:688-9.
39. Cairns AP, Wright SA, Taggart AJ, Coward SM, Wright GD. An open study of pulse pamidronate treatment in severe ankylosing spondylitis, and its effect on biochemical markers of bone turnover. Ann Rheum Dis 2005;64:338-9.
40. Sambrook PN, Kotowicz M, Nash P et al. Prevention and treatment of glucocorticoid-induced osteoporosis: A comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 2003;18:919-24.
41. Clegg DO, Reda DJ, Weisman MH et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2004-12.
42. Dougados M, Boumier P, Amor B. Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients. Br Med J (Clin Res Ed) 1986;293: 911-4.
43. Schmidt WA, Wierth S, Milleck D, Droste U, Gromnica-Ihle E. [Sulfasalazine in ankylosing spondylitis: A prospective, randomized, double-blind placebo-controlled study and comparison with other controlled studies]. Z Rheumatol 2002;61:159-67.
44. Altan L, Bingol U, Karakoc Y, Aydiner S, Yurtkuran M, Yurtkuran M. Clinical investigation of methorexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2001;30:255-9.
45. Gossec L, van der Heijde D, Melian A et al. Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Am Rheum Dis 2005;64:1563-7.
46. Sydnes OA. Comparison of piroxicam with indomethacin in ankylosing spondylitis: A double-blind crossover trial. Br J Clin Pract 1981;36:40-4.
47. Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis: A systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006;65:423-32.
48. Boulos P, Dougados M, Macleod SM, Hunsche E. Pharmacological treatment of ankylosing spondylitis: A systematic review. Drugs 2005;65:2111-27.
49. Ramey DR, Watson DJ, Yu C, Bolognese JA, Curtis SP, Reicin AS. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: An updated combined analysis. Curr Med Res Opin 2005;21:715-22.
50. White WB, West CR, Borer JS et al. Risk of cardiovascular events in patients receiving celecoxib: A meta-analysis of randomized chnical trials. Am J Cardiol 2007;99:91-8.
51. Dougados M, Nguyen M, Caporal R et al. Ximoprofen in ankylosing spondylitis. A double blind placebo controlled dose ranging study. Scand J Rheumatol 1994;23:243-8.
52. Dougados M, Gueguen A, Nakache JP et al. Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal antiinflammatory drug trial. Rheumatology 1999;38:235-44.
53. Dougados M, Behier JM, Jolchine I et al. Efficacy of celeooxib, a cyclooxygenase 2-specific inhibitor, in this treatment of ankylosing spondylitis: A six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001;44:180-5.
54. van der Heijde D, Baraf HS, Ramos-Remus C et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: Results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005;52:1205-15.
55. Doury P, Roux H. Isoxicam vs ketoprofen in ankylosing spondylitis. Br J Clin Pharmacol 1986;22(Suppl 2):157S-60S.
56. Gibson T, Laurent R. Sulindac and indomethacin in this treatment of ankylosing spondylitis: A double-blind cross-over study. Rheumatol Rehabil 1980;19:189-92.
57. Santo JE, Queiroz MV. Oxaprozin versus diclofenac sodium in the treatment of ankylosing spondylitis. J Int Med Res 1988;16:150-6.
58. Schwarzer AC, Cohen M, Arnold MH, Kelly D, McNaught P, Brooks PM. Tenoxicam compared with diclofenac in patients with ankylosing spondylitis. Curr Med Res Opin 1990;11:648-53.
59. Wordsworth BP, Ebringer RW, Coggins E, Smith S. A double-blind cross-over trial of fenoprofen and phenylbutazone in ankylosing spondylitis. Rheumatol Rehabil 1980;19:260-3.
60. Villa Alcazar LF, de Buergo M, Rico LH, Montull FE. Aceclofenac is as safe and effective as tenoxicam in the treatment of ankylosing spondylitis: A 3 month multi-center comparative trial. Spanish Study Group on Aceclofenac in Ankylosing Spondylitis. J Rheumatol 1996;23:1194-9.
61. Mena HR, Willkens RF. Treatment of ankylosing spondylitis with flurbiprofen or phenylbutazone. Eur J Clin Pharmacol 1977;11:263-6.
62. Calin A, Grahame R. Double-blind cross-over trial of flurbiprofen and phenylbutazone in ankylosing spondylitis. Br Med J 1974;4:496-9.
63. Lomen PL, Turner LF, Lambom KR, Brinn EL, Settler LP. Flurbiprofen in the treatment of ankylosing spondylitis. A comparison with phenylbutazone. Am J Med 1986;80:120-6.
64. Lehtinen K, Kaarela K, Makisara P, Holttinen K, Gordin A. Tolerability and efficacy of a slow-release indomethacin tablet in ankylosing spondylitis. Br J Rheumatol 1984;23:52-6.
65. Regalado RG. Butacote and ibuprofen: A comparative assessment in rheumatic diseases in general practice. J Int Med Res 1977;5(Suppl 2):70-6.
66. Carcassi C, La Nasa G, Perpignano G. A 12-week double-blind study of the efficacy, safety and tolerance of pirazolac b.i.d. compared with indomethacin t.i.d. in patients with ankylosing spondylitis. Drugs Exp Clin Res 1990;16:29-37.
67. Harkness AJ, Burry HC, Grahame R. A trial of feprazone in ankylosing spondylitis. Rheumatol Rehabil 1977;16:158-61.
68. Treadwell BL, Tweed JM. Ketoprofen (Orudis) in ankylosing spondylitis. N Z Med J 1975;81:411-3.
69. Jessop JD. Double-blind study of ketoprofen and phenylbutazone in ankylosing spondylitis. Rheumatol Rehabil 1976(Suppl.):S37-42.
70. Wanders A, van der Haijde D, Landewe R et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trial. Arthritis Rheum 2005;52:1756-65.
71. Chen J, Liu C. Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. J Rheumatol 2006;33:722-31.
72. D'Agostino MA, Olivieri I. Enthesitis. Best Pract Res Clin Rheumatol 2006;20: 473-86.
73. Rampton DS, Sladen GE. Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs, Postgrad Med J 1981;57:297-9.
74. Kaufmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 1987;107:513-6.
75. Hovde O, Farup PG. NSAID-induced irreversible exacerbation of ulcerative colitis. J Clin Gastroenterol 1992;15:160-1.
76. El Miedany Y, Youssef S, Ahmed I. El Gaafary M. The gastrointestinal safety and affect on disease actvily of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol 2006;101:311-7.
77. Sandborn WJ, Stenson WF, Brynskov J et al. Safety of celecoxib in patients with ulcerative colitis in remission: A randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol 2006;4:203-11.
78. Rudwaleit M, van der Haijde D, Khan MA, Braun J, Sieper J. How to diagnose axial spondyloarthritis early. Ann Rheum Dis 2004;63:535-43.
79. Oostveen J, Prevo R, den Boer J, van do Laar M. Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroillitis on plain radiography. A prospective, longitudinal study. J Rheumatol 1999;26: 1953-8.
80. Ahlstrom H, Feltellus N, Nyman R, Hallgren R. Magnetic resonance imaging of sacroiliac joint inflammation. Arthritis Rheum 1990;33:1763-9.
81. Braun J, Bollow M, Eggens U, Konig H, Distler A, Sieger J. Use of dynamic magnetic resonance imaging with fast Imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 1994;37:1039-45.
82. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet 2004;364:2021-9.
83. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-44.
84. Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
85. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: Population based nested case-oontrol analysis. Br Med J 2005;330:1366.
86. Graham DJ, Campen D, Hui R et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study. Lancet 2005;365:475-81.
87. Solomon DH, Schneeweiss S, Glynn RJ et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004;109:2068-73.
88. Caldwell 8, Aldington S, Weatherall M, Shirtcliffe P, Beasley R. Risk of cardiovascular events and celecoxib: A systematic review and meta-analysis. J R Soc Med 2006;99:132-40.
89. Garcia Rodriguez LA, Gonzalez-Perez A. Long-term use of non-steroidal anti-inflammatory drugs and to risk of myocardial infarction in the general population. BMC Med 2005;3:17.
90. Keamey PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Br Med J 2006;332:1302-8.
91. Hemandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA. Non-steroidal anti-inflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006;98:266-74.
92. Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006;33:2167-72.
93. Palm O, Moum B, Ongre A, Gran JT. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: A population study (the IBSEN study). J Rheumatol 2002;29:511-5.